BCR-ABL1 kinase: hunting an elusive target with new weapons

Tomasz Skorski

doi:10.1016/j.chembiol.2011.11.001

BCR-ABL1 kinase: hunting an elusive target with new weapons

Chem Biol. 2011 Nov 23;18(11):1352-3. doi: 10.1016/j.chembiol.2011.11.001.

Author

Tomasz Skorski¹

Affiliation

¹ Department of Microbiology and Immunology, Temple University, School of Medicine, Philadelphia, PA 19140, USA. [email protected]

Abstract

Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.

Publication types

Comment

Abstract

Publication types

Grants and funding